Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exablate BBBD With Doxorubicin in Pediatric DIPG
NCT05615623Phase 2Active, not recruiting
- Sponsor
- Insightec
- Start
- Jan 2023
- Primary completion
- Jun 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in diffuse intrinsic pontine glioma (DIPG), sponsored by Insightec. Primary endpoint: Adverse Events at 2 years. Started Jan 2023; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT05615623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615623.